A Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease

Steroid-refractory chronic graft-versus-host disease (cGvHD) carries a poor prognosis with no agreed-upon algorithm for treatment. Since both B and T cells contribute to the pathophysiology of cGvHD, we conducted a Phase 1 study in subjects with steroid-refractory cGvHD using the anti-CD52 antibody...

Full description

Saved in:
Bibliographic Details
Main Authors: Nikiforow, Sarah, Kim, Haesook T., Bindra, Bhavjot, McDonough, Sean, Glotzbecker, Brett, Armand, Philippe, Koreth, John, Ho, Vincent T., Alyea, Edwin P., Blazar, Bruce R., Ritz, Jerome, Soiffer, Robert J., Antin, Joseph H., Cutler, Corey S.
Format: Artigo
Language:Inglês
Published: 2013
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3642980/
https://ncbi.nlm.nih.gov/pubmed/23416855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2013.02.009
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items